Article
Oncology
Fu-Jia Liu, Wen-Yan Cheng, Xiao-Jing Lin, Shi-Yang Wang, Tian-Yi Jiang, Ting-Ting Ma, Yong-Mei Zhu, Yang Shen
Summary: This study demonstrated that the combination of MFC MRD and molecular MRD can establish prognostic value in AML patients with specific genetic lesions. After two cycles of consolidation, MFC MRD showed independent predictive significance for clinical outcomes, highlighting the importance of integrating different MRD assessment methods based on genetic characteristics of AML.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Kritika Srinivasan Rajsri, Nainita Roy, Sohini Chakraborty
Summary: Acute myeloid leukemia (AML) is a blood cancer characterized by immature blood cells called leukemic blasts. Leukemia stem cells (LSCs) are resistant to chemotherapy and can cause disease relapse. Understanding the molecular basis of LSCs is important in identifying and targeting these cells for more effective treatment.
Article
Oncology
Claudia Nunez-Torron Stock, Carlos Jimenez Chillon, Fernando Martin Moro, Juan Marquet Palomanes, Kyra Velazquez Kennedy, Miguel Piris Villaespesa, Ernesto Roldan Santiago, Eulalia Rodriguez Martin, Anabelle Chinea Rodriguez, Valentin Garcia Gutierrez, Gemma Moreno Jimenez, Javier Lopez Jimenez, Pilar Herrera Puente
Summary: Secondary acute myeloid leukemia (s-AML) patients who undergo allogeneic stem-cell transplant (HSCT) have worse survival compared to de novo AML patients, particularly in those who achieve complete remission (CR) before transplant. Factors contributing to the poorer prognosis include an increased risk of relapse and non-relapse mortality. However, patients receiving MAC conditioning had comparable outcomes, regardless of leukemia ontogeny.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
Lisa Weijler, Florian Kowarsch, Matthias Woedlinger, Michael Reiter, Margarita Maurer-Granofszky, Angela Schumich, Michael N. Dworzak
Summary: Acute myeloid leukemia (AML) is the second most common and aggressive type of leukemia in children and adolescents. Flow cytometry is an effective method to monitor the number of remaining leukemic cells in the bone marrow of AML patients, but the data patterns are complex and difficult to identify. An automatic assessment approach using a semi-supervised machine learning model has been developed to address these challenges.
Review
Immunology
Justin Loke, Richard Buka, Charles Craddock
Summary: While most AML patients achieve complete remission with intensive chemotherapy, many face a risk of relapse if treated with chemotherapy alone. Allogeneic stem cell transplant has become a key treatment strategy for AML patients, especially for those in first complete remission and advanced stages. Despite a decrease in transplant-related mortality, there remains a need to address the risk of disease relapse.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Jean Philippe Vial, Nicolas Lechevalier, Francis Lacombe, Pierre-Yves Dumas, Audrey Bidet, Thibaut Leguay, Francois Vergez, Arnaud Pigneux, Marie C. Bene
Summary: In acute myeloid leukemia (AML), assessment of minimal/measurable residual disease (MRD) can be done using molecular markers or immunophenotypic features through multiparameter flow cytometry (MFC). The use of artificial intelligence tools, such as Flow-Self-Organizing-Maps (FlowSOM), allows for unsupervised analysis of MFC data, leading to a new and objective way of evaluating MRD even in AML patients without molecular markers. This approach shows promise for monitoring response to therapy in hematological malignancies.
Article
Hematology
Fabio Guolo, Carmen Di Grazia, Paola Minetto, Anna Maria Raiola, Marino Clavio, Maurizio Miglino, Elisabetta Tedone, Paola Contini, Rosa Mangerini, Annalisa Kunkl, Nicoletta Colombo, Girolamo Pugliese, Enrico Carminati, Riccardo Marcolin, Monica Passannante, Samuele Bagnasco, Federica Galaverna, Teresa Lamparelli, Filippo Ballerini, Antonia Cagnetta, Michele Cea, Marco Gobbi, Andrea Bacigalupo, Roberto Massimo Lemoli, Emanuele Angelucci
Summary: The study highlighted the importance of pretransplant MRD evaluation combined with transplant-related factors in identifying AML patients at higher risk for relapse. This combined approach may help in defining a more effective overall transplant strategy.
EUROPEAN JOURNAL OF HAEMATOLOGY
(2021)
Review
Oncology
Christian M. Vonk, Adil S. A. Al Hinai, Diana Hanekamp, Peter J. M. Valk
Summary: Although most AML patients achieve CR after initial induction chemotherapy, residual leukemic cells may lead to relapse, with MRD serving as a prognostic marker. Molecular techniques like NGS offer a sensitive assessment of MRD markers, but face challenges such as limited sensitivity/specificity and difficulty in distinguishing mutations. Multiple studies have explored the association between MRD detection by molecular assays and AML relapse, highlighting limitations, challenges, and opportunities.
Article
Oncology
Xiaozhe Li, Beihui Huang, Junru Liu, Meilan Chen, Jingli Gu, Juan Li
Summary: Minimal residual disease (MRD) evaluation by multiparameter flow cytometry (MFC) at 3 months after first-line therapy completion in newly diagnosed AL amyloidosis patients is feasible and associated with improved organ response rates and longer progression-free survival (PFS) over a long follow-up period.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Selina M. Luger
Summary: The Oncology Grand Rounds series aims to provide readers with a better understanding of applying key study results to their clinical practice through case presentations and literature reviews.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Jun Kong, Meng-Ge Gao, Ya-Zhen Qin, Yu Wang, Chen-Hua Yan, Yu-Qian Sun, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Su Zhao
Summary: This study aimed to analyze the dynamic changes of MLL-PTD peri-transplantation and determine the best threshold for predicting relapse after transplantation. The study included 48 patients with MLL-PTD AML or MDS-EB who underwent allo-HSCT. The results showed that MLL-PTD after transplantation can serve as an effective indicator for predicting relapse. The expression level of MLL-PTD >= 1.0% was identified as the optimal cut-off value for predicting hematological relapse after allo-HSCT.
Article
Oncology
Mohamed E. Salama, Gregory E. Otteson, Jon J. Camp, Jansen N. Seheult, Dragan Jevremovic, David R. Holmes, Horatiu Olteanu, Min Shi
Summary: Flow cytometric immunophenotyping is critical in detecting minimal residual disease (MRD) in patients with chronic lymphocytic leukemia (CLL). In this study, a deep neural network (DNN) approach was evaluated for its performance in detecting CLL MRD, and it was found to have high accuracy and improve workflow efficiency.
Article
Medicine, General & Internal
Man Chen, Minjing Fu, Meiwei Gong, Yajing Gao, Aixian Wang, Wei Zhao, Xueying Wu, Hui Wang
Summary: Full spectrum flow cytometry has made a breakthrough in detecting minimal residual disease (MRD) in acute myeloid leukemia (AML), and a new panel has been discovered for MRD detection. A 24-color full-spectrum flow cytometry panel was established, including CD45, CD117, CD34, etc. The markers used in this panel were not only limited to MRD observation in AML, but also could be used for fine clustering of bone marrow cells. The expression of CD96 and CD200 was significantly enhanced in AML-MRD samples compared to normal bone marrow samples. These results provide important basis for the auxiliary diagnosis, prognosis judgment, treatment guidance, and immune regulation in AML.
Article
Multidisciplinary Sciences
Mayumi Sugita, Roman Galetto, Hongliang Zong, Nathan Ewing-Crystal, Vicenta Trujillo-Alonso, Nuria Mencia-Trinchant, Winnie Yip, Stephanie Filipe, Celine Lebuhotel, Agnes Gouble, Duane C. Hassane, Julianne Smith, Gail J. Roboz, Monica L. Guzman
Summary: This study reports the design and characterization of allogeneic CD123-targeted CAR-T cells as a therapeutic approach for acute myeloid leukemia.
NATURE COMMUNICATIONS
(2022)
Review
Oncology
Gloria Paz Contreras Yametti, Talia H. Ostrow, Sylwia Jasinski, Elizabeth A. Raetz, William L. Carroll, Nikki A. Evensen
Summary: Acute lymphoblastic leukemia minimal residual disease (MRD) is residual leukemia cells present after achieving complete remission, with significant impact on prognosis. Rapid reduction of MRD indicates leukemia sensitivity to therapy, aiding in risk stratification and treatment adjustment.
Article
Hematology
Xiang Wang, Xue-Fei Liu, Qian-Nan Shang, Xing-Xing Yu, Ze-Ying Fan, Xun-Hong Cao, Ming-Rui Huo, Ying-Jun Chang, Xiao-Su Zhao, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiang-Yu Zhao
Summary: This study found that donors with activating KIR genes, specifically KIR2DS1, KIR2DS3, and KIR3DS1, were associated with an increased risk of EBV reactivation after HSCT. The risk was higher when the cognate ligands for the corresponding activating receptors were absent. Measures to prevent EBV reactivation in patients with donors carrying activating genes could improve patient prognosis after HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Immunology
Xu-Ying Pei, Xue-Fei Liu, Xiang-Yu Zhao, Meng Lv, Xiao-Dong Mo, Ying-Jun Chang, Qian-Nan Shang, Yu-Qian Sun, Yu-Hong Chen, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Summary: This study compared the antiviral abilities of transplant donor and third-party CMV-CTLs in treating CMV infection, and found that they have similar long-term antiviral efficacy. The clinical study further showed that patients receiving either donor or third-party CMV-CTLs had comparable clinical responses without significant therapy-related toxicity.
CELLULAR & MOLECULAR IMMUNOLOGY
(2022)
Article
Medicine, General & Internal
Yu Wang, Yuan Kong, Hong-Yan Zhao, Yuan-Yuan Zhang, Ya-Zhe Wang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Summary: The study aimed to investigate the efficacy and tolerability of N-acetyl-L-cysteine (NAC) prophylaxis in reducing Poor Graft Function (PGF) or Prolonged Isolated Thrombocytopenia (PT) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The results showed that NAC prophylaxis effectively reduced the incidence of PGF and PT, and it was well tolerated in haploidentical HSCT.
Article
Hematology
Xiaodi Ma, Yangyang Zuo, Zhengli Xu, Yuanyuan Zhang, Yifei Cheng, Tingting Han, Pan Suo, Yuqian Sun, Feifei Tang, Fengrong Wang, Chenhua Yan, Yuhong Chen, Yu Wang, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang, Lanping Xu
Summary: This study retrospectively compared the characteristics and outcomes of patients with hepatitis-associated aplastic anemia (HAAA) and non-hepatitis-associated aplastic anemia (non-HAAA) who underwent haploidentical hematopoietic stem cell transplantation (haplo-HSCT). The results showed no significant differences in neutrophil engraftment time, overall survival rates, and liver event-free survival rates between HAAA and non-HAAA patients. These findings suggest that haplo-HSCT is a feasible treatment option for HAAA when HLA-matched donors are not available, with low risks of transplant-related mortality and complications.
ANNALS OF HEMATOLOGY
(2022)
Letter
Biophysics
Lanping Xu, Yue Lu, Jing Chen, Shuwen Sun, Shaoyan Hu, Shunqing Wang, Xuedong Wu, Yuan Sun, Dingming Wan, Yajing Xu, Hui Jiang, Chunfu Li, Mei Lan, Erlie Jiang, Fei Li, Sixi Liu, Yongmin Tang, Fan Lin, Peihua Lu, Chengjuan Luo, Xiaojun Huang
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Cuiyan Zhou, Fengmei Zheng, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: Previous studies have shown that TP53 mutation is associated with insufficient therapy response and unfavorable prognosis in acute lymphoblastic leukemia (ALL). However, a new study suggests that TP53 mutation may not impact survival in ALL patients after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Hematology
Yuewen Wang, Xiaodong Mo, Yifei Cheng, Yuhong Chen, Meng Lv, Fengrong Wang, Chenhua Yan, Wei Han, Huan Chen, Lanping Xu, Yu Wang, Xiaohui Zhang, Kaiyan Liu, Xiaojun Huang, Yingjun Chang
Summary: CD34(+) cell dose has an impact on hematopoietic recovery in ALL patients, especially in pre-HSCT MRD-positive patients, where higher CD34(+) cell doses are associated with faster neutrophil and platelet engraftment. However, we did not observe direct correlations between CD34(+) cell dose and relapse, TRM, LFS, or OS.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Article
Oncology
Qian Jiang, Zongru Li, Yazhen Qin, Weiming Li, Na Xu, Bingcheng Liu, Yanli Zhang, Li Meng, Huanling Zhu, Xin Du, Suning Chen, Yang Liang, Yu Hu, Xiaoli Liu, Yongping Song, Lichuang Men, Zi Chen, Qian Niu, Hengbang Wang, Ming Lu, Dajun Yang, Yifan Zhai, Xiaojun Huang
Summary: This study evaluated the safety and efficacy of Olverembatinib in Chinese adults with TKI-resistant CML, and found significant antileukemic activity in patients in the chronic phase and accelerated phase.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2022)
Article
Biology
Qi Wen, Zheng-Li Xu, Yu Wang, Meng Lv, Yang Song, Zhong-Shi Lyv, Tong Xing, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong
Summary: This study found that glycolysis plays a critical role in T cell activation and induction of human aGvHD. Regulating glycolysis offers a potential pathogenesis-oriented therapeutic strategy for aGvHD patients, and the combination of GCs and glycolysis inhibitors may be a novel first-line combination therapy for aGvHD patients.
SCIENCE CHINA-LIFE SCIENCES
(2023)
Review
Hematology
Rui Ma, Xin-Tong Liu, Ying-Jun Chang
Summary: Allo-HSCT is still a curative approach for ALL, and it can be combined with targeted therapy and immunotherapy to improve transplant outcomes. Future directions should focus on reducing relapse and nonrelapse mortality to further improve outcomes for patients with ALL.
EXPERT REVIEW OF HEMATOLOGY
(2022)
Article
Hematology
Ting Huang, Lanping Xu, Xiaohui Zhang, Yingjun Chang, Xiaodong Mo, Yuqian Sun, Xiaojun Huang, Yu Wang
Summary: This study compared the clinical outcomes of AML patients with and without TP53 mutations who underwent haplo-HSCT, and found no significant differences in 2-year clinical outcomes between the two groups. Multivariable analysis also showed that TP53 mutations had no significant impact on relapse rate, mortality rate, overall survival, graft-versus-host disease, leukemia-free survival or GvHD-free/relapse-free survival. The findings suggest that patients with AML with TP53 mutations may at least partially benefit from haplo-HSCT.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Xin-Xin Liu, Xin-An Pan, Meng-Ge Gao, Jun Kong, Hao Jiang, Ying-Jun Chang, Xiao-Hui Zhang, Yu Wang, Kai-Yan Liu, Zhong Chen, Xiao-Su Zhao, Xiao-Jun Huang
Summary: This study found that EVI1 high expression was associated with poor prognosis in the Non-KMT2A-MLLT3 group and both KMT2A-MLLT3 and Non-KMT2A-MLLT3 patients who received chemotherapy alone had poorer prognosis than those who received allogeneic hematopoietic stem cell transplant. High EVI1 expression was shown to have an adverse effect on AML with KMT2A rearrangement in different risk stratification subtypes.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
(2023)
Review
Medicine, General & Internal
Wei Sun, Xiaojun Huang
Summary: Allogeneic hematopoietic stem cell transplantation is the standard treatment for adult acute lymphoblastic leukemia, and the development of immunotherapy has expanded treatment options for relapsed or refractory ALL patients.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Yongzhan Zhang, Lu Bai, Yifei Cheng, Aidong Lu, Yu Wang, Jun Wu, Xiaohui Zhang, Yingxi Zuo, Lanping Xu, Yueping Jia, Xiaojun Huang, Leping Zhang
Summary: This study found that allo-HSCT, especially haplo-HSCT, can improve survival and reduce relapse in high-risk T-ALL children. Minimal residual disease re-emergence, age, and high white blood cell count are independent risk factors that affect prognosis.
CHINESE MEDICAL JOURNAL
(2022)